Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 4, 2012, Pages 751-754

  Schwandt, Anita ^a   Mekhail, Tarek ^b,d   Halmos, Balazs ^a,d   O'Brien, Timothy ^c   Ma, Patrick C ^a,d   Fu, Pingfu ^d   Ivy, Percy ^e   Dowlati, Afshin ^a,d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Cancer Therapy and Evaluation Program   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECATECARIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MALE; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 84858784067     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824abca2     Document Type: Article

References (14)

1. Bailly C , Goossens JF, Laine W, et al. Formaldehyde-induced alkylation of a 2'-aminoglucose rebeccamycin derivative to both A.T and G.C base pairs in DNA. J Med Chem 2000;43:4711-4720.
2. Facompre M, Baldeyrou B, Bailly C, et al. DNA targeting of two new antitumour rebeccamycin derivatives. Eur J Med Chem 2002;37:925-932. (Pubitemid 36349001)
3. Bush JA, Long BH, Catino JJ, Bradner WT, Tomita K. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo) 1987;40:668-678. (Pubitemid 17072164)
4. Bailly C, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M, Waring MJ. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol Pharmacol 1998;53:77-87. (Pubitemid 28068374)
5. Kaneko T, Wong H, Utzig J, Doyle T. Water soluble derivatives of rebeccamycin. J Antibiot (Tokyo) 1990;43:125-127.
6. Dowlati A, Hoppel CL, Ingalls ST, et al. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J Clin Oncol 2001;19:2309-2318. (Pubitemid 32372326)
7. Tolcher AW, Eckhardt SG, Kuhn J, et al. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 2001;19:2937-2947. (Pubitemid 32538204)
8. Merchant J, Tutsch K, Dresen A, et al. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res 2002;8:2193-2201. (Pubitemid 34753590)
9. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667. (Pubitemid 29075255)
10. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-5447. (Pubitemid 46623178)
11. Jotte R, Von Pawel J, Spigel DR, et al Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). J Clin Oncol 2011;29:2011 (Suppl; abstr 7000)
12. Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867-873.
13. Mascaux C, Paesmans M, Berghmans T, et al.; European Lung Cancer Working Party (ELCWP). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36.
14. Dowlati A, Levitan N, Gordon NH, et al. Phase II and pharmacokinetic/ pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001;47:141-148. (Pubitemid 32662319)